Neurodegeneration Pathway-Specific Mutagenesis
Principal Investigator
George Carlson, PhD
McLaughlin Research Institute for Biomedical Sciences, Inc.
Great Falls, MT, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$168,095
Active Dates
March 31, 1998 - March 30, 2000
Grant ID
A1998026
Summary
Most Alzheimer’s disease does not “run in families.” Only rare families are afflicted with Alzheimer’s disease that is caused by inherited defects in any one of three genes. In these unfortunate families, approximately half the children inherit the defective gene and are destined to develop Alzheimer’s disease in late middle age. Although the most common form of Alzheimer’s occur in old age and does not have a simple pattern of inheritance, the genetic make-up of the individual does influence the chance of becoming ill. Rather than a single gene, many genes are involved. Identification of the genes that influence Alzheimer’s disease will help in developing treatments that could low the progress of disease or even prevent it from occurring. Identification of the defective genes causing the familial form of Alzheimer’s disease was a major accomplishment, even though only a single gene is involved in each family. When many genes are involved, study of human populations is extremely difficult. The laboratory mouse is much more suitable for studies of this kind. Unfortunately, due to their short lifespan, very few mutations relevant to diseases old age have been identified in mice. We propose to induce mutation that are relevant to Alzheimer’ disease and to a related disease by using a DNA-damaging chemical. We will specifically select for mutations that affect only mice that lack the amyloid precursor protein (APP) gene or the prion protein (PrP) gene. A fragment of APP protein is deposited in the brains of Alzheimer’s disease patient and is associated with the death of brain cells. An improperly folded form of PrP causes prion diseases , which also cause brain cell death. Although much is known about how these protein act in disease, their normal function is unknown. Genes involved in their normal function are likely to also affect disease processes involving the proteins. We are exploiting the power of mouse genetics to identify genes involved in human brain disorders.
Related Grants
Alzheimer's Disease Research
Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Emiliano Zamponi, PhD
Current Organization
Columbia University
Mechanisms of Inhibitory Neuron Vulnerability to Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Emiliano Zamponi, PhD
Current Organization
Columbia University
Alzheimer's Disease Research
Targeting Brain Cell Miscommunication to Restore Memory in Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Amira Latif-Hernandez, PhD
Current Organization
Stanford University
Targeting Brain Cell Miscommunication to Restore Memory in Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Amira Latif-Hernandez, PhD
Current Organization
Stanford University
Alzheimer's Disease Research
Progranulin as a Potential Therapeutic Target for Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Andrew Nguyen, PhD
Current Organization
Saint Louis University
Progranulin as a Potential Therapeutic Target for Alzheimer's Disease
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Andrew Nguyen, PhD
Current Organization
Saint Louis University